|
01 Jun 2020 |
VBL Presents Positive Interim Data from the OVAL Phase 3 Pivotal Study in Ovarian Cancer at the ASCO20 Annual Meeting, Showing 58% or Higher Objective Response Rate
|
|
01 Jun 2020 |
Ocugen to Discontinue Phase 3 oGVHD Trial
|
|
01 Jun 2020 |
Longeveron Announces Japanese Approval of Clinical Trial for Treatment of Aging Frailty With Longeveron's Stem Cells
|
|
01 Jun 2020 |
BioMarin Provides Highlights of 4 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
|
|
31 May 2020 |
NKMax America Presents Promising Clinical Research Findings at 2020 ASCO Virtual Conference
|
|
30 May 2020 |
Allogene Therapeutics, with Collaborator Servier, Reports Positive Results from its Phase 1 ALPHA Study of ALLO-501 in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology Annual Meeting
|
|
30 May 2020 |
Oncolytics Biotech® Presents Clinical Proof-of-Concept Data in Multiple Myeloma at the ASCO Virtual Annual Meeting
|
|
30 May 2020 |
Marker Therapeutics Reports Interim Results of its MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
|
|
29 May 2020 |
Yescarta® (Axicabtagene Ciloleucel) Demonstrates High Rates of Response in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
|
|
29 May 2020 |
AgeX Therapeutics and Sernova to Collaborate to Engineer Universal Locally Immune Protected Cell Therapies for Type I Diabetes and Hemophilia A
|
|
29 May 2020 |
SPEAR T-cells Targeting MAGE-A4 Demonstrate New Responses in Esophagogastric Junction (EGJ), Lung, and Head and Neck Cancers – Late Stage Development Initiated in EGJ Cancer
|
|
28 May 2020 |
Iovance Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from C-144-01 Clinical Study in Advanced Melanoma
|
|
26 May 2020 |
Expression Therapeutics Announces IND Approval by the FDA for Hemophilia A Gene Therapy
|
|
26 May 2020 |
Atara Biotherapeutics Presents Data Demonstrating Safety & Sustained Disability Improvement at 12 Months with ATA188 in Patients with Progressive Multiple Sclerosis in Late-Breaking e-Poster at the 2020 European Academy of Neurology Virtual Congress
|
|
26 May 2020 |
Tollys closes Series A financing of €2.3 million
|
|
22 May 2020 |
European Medicines Agency Validates Bristol Myers Squibb’s Applications for Idecabtagene Vicleucel (Ide-cel, bb2121) and CC-486
|
|
21 May 2020 |
Kleo Pharmaceuticals and Celularity Enter into Research Collaboration to Rapidly Develop Allogeneic NK Cell Combination Therapies for COVID-19 and Multiple Myeloma
|
|
20 May 2020 |
Poseida Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of P-PSMA-101 Autologous CAR-T for Metastatic Castration-Resistant Prostate Cancer
|
|
19 May 2020 |
Arbutus Announces Single-Dose Week 12 Data in Chronic Hepatitis B Subjects with 60 mg AB-729 Demonstrating a Significant and Continuous Reduction in HBsAg
|
|
19 May 2020 |
AveXis receives EC approval and activates “Day One” access program for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA)
|
|
18 May 2020 |
CARsgen Therapeutics Receives IND Clearance from the US FDA for CT041 CLDN18.2-CAR-T Cells
|
|
18 May 2020 |
Bone Therapeutics treats first patients in pivotal JTA-004 phase III knee osteoarthritis study
|
|
16 May 2020 |
Orchard Therapeutics Presents New Interim Data from OTL-203 Proof-of-concept Study for MPS-I
|
|
16 May 2020 |
Editas Medicine Presents Pre-Clinical Data Supporting the use of CRISPR-Cas12a to Edit Induced Pluripotent Stem Cells for the Development of Engineered Cell Immunotherapies
|
|
16 May 2020 |
Pfizer’s New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study
|
